Arcus Biosciences Announces Participation at Upcoming Investor C - Tucson News Now

Arcus Biosciences Announces Participation at Upcoming Investor Conference

HAYWARD, Calif. --(BUSINESS WIRE)

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conferenceon Tuesday, June 12, 2018at 8:40 am PT at the Terranea Resort, in Rancho Palos Verdes, CA.

Individuals may access the live audio webcast by visiting the “Events & Presentations” section of the Company’s website at https://investors.arcusbio.com/investors/investor-relations/default.aspx. A replay of the webcast will be available for 30 days following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an anti-TIGIT antibody, which are in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology, and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Arcus Biosciences, Inc.
Jennifer Jarrett, 510-694-6261
jjarrett@arcusbio.com
or
Nicole Arndt, 510-284-4728
narndt@arcusbio.com

Copyright Business Wire 2018

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and have questions or removal requests please contact pressreleases@franklyinc.com

Powered by Frankly